Pneumococcal polysaccharide vaccine: Cost-effectiveness recommendations in adults

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 5, Issue 5, 2005, Pages 541-551

  Plans Rubió, Pedro ^a  

^a Universtitat de Barcelona   (Spain)

Author keywords

Evaluative studies; Pneumococcal polysaccharide vaccine; Vaccination recommendations

Indexed keywords

CHLORAMPHENICOL; COTRIMOXAZOLE; ERYTHROMYCIN; PENICILLIN G; PNEUMOCOCCUS VACCINE;

ADULT; CASE CONTROL STUDY; CHRONIC PATIENT; CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; IMMUNOCOMPETENCE; INFECTION RISK; LOBAR PNEUMONIA; NONHUMAN; POPULATION RESEARCH; PROTECTION; RANDOMIZATION; REVIEW; RISK FACTOR; SIDE EFFECT; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

EID: 27744433300     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.5.5.541     Document Type: Review

References (68)

1. Felson DS, Musher DM. Pneumococcal polysaccharide vaccine. In: Vaccines, fourth edition. Plotkin SA, Orenstein WA (Eds), Saunders, PA, USA 529-588 (2004).
2. Advisory Committee on Immunization Practices. Prevention of pneumococcal disease: Recommendations of the Advisory Committee on Immunization Practices. MMWR 46, 1-24 (1997).
3. Task Force on Community Prevention Service. Recommendations regarding interventions to improve vaccination coverage in children, adolescents and adults. Am. J. Prev. Med. 18(Suppl.), 92-140 (2000).
4. National Centers for Disease Control and Prevention (CDC). Defining the public health impact of drug-resistant Streptococus pneumoniae: report of a working group. MMWR 45, 1-20 (1996).
5. Doern GV, Brueggemann AB, Huynh H, Wingert E. Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997-98. Emerg. Infect. Dis. 5, 757-765 (1999).
6. Mangtani P, Cutts F, Hall AJ. Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries. Lancet Infect. Dis. 2, 71-78 (2003).
7. Ortqvist A. Pneumococcal vaccination: current and future issues. Eur. Respir. J. 18, 184-195 (2001).
8. Gable CB, Botteman M, Savage G, Joy K. The cost-effectiveness of pneumococcal vaccination stratregies. Pharmacoeconomics 12, 161-174 (1997).
9. Beutels P, Postma MJ. Economic evaluations of adult pneumococcal vaccination strategies. Expert Rev. Pharmacoeconomics Outcomes Res. 1, 47-58 (2001).
10. Plans P. Cost-effectiveness of 23-valent antipneumococcal vaccination in Catalonia (Spain). Gac. Sanit. 16, 392-400 (2002).
11. Plans Rubió P, Garrido Morales P, Salleras Sanmartí Ll. Coste-efectividad de la vacunación neumocócica en Cataluña. Rev. Esp. Salud Pública 69, 409-417 (1995).
12. Sisk JE, Whang W, Butler JC, Sneller VP, Whitney CG. Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann. Intern. Med. 138, 960-968 (2003).
13. Singletton JA, Greby SM, Wooter KG, Walker FJ, Strikas R. Influenza, pneumonia, and tetanus toxioid vaccination of adults - United States, 19937. MMWR CDC Survill. Summ. C49, 39-62 (2000).
14. CDC. Influenza and pneumococcal vaccination levels among persons aged ≥ 65 years - United States, 1999. MMWR 50, 532-537 (2001).
15. Smit P, Oberholzer D, Hayden-Smith S, Koornhof HJ, Hilleman MR. Protective efficacy of pneumococcal polysaccharide vaccines. JAMA 12(238), 2613-2616 (1977).
16. Riley ID, Tarr PI, Andrews M et al, Immunisation with a polyvalent pneumococcal vaccine. Reduction of adult respiratory mortality in a New Guinea Highlands community. Lancet 1, 1338-1341 (1977).
17. Simberkoff MS, Cross AP, Al-Ibrahim M et al. Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Co-operative Study. N. Engl. J. Med. 315, 1318-1327 (1986).
18. French N, Nakiyingi J, Carpenter LM et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and Placebo-controlled trial. Lancet 355, 2106-2111 (2000).
19. Gaillat J, Zmirou D, Mallaret MR et al. Clinical trial of an antipneumocccal vaccine in elderly subjects living in institutions. Rev. Epidemiol. Sante Publique 33, 437-444 (1985).
20. Leech JA, Gervais A, Ruben FL. Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease. CMAJ 136, 361-365 (1987).
21. Davis AL, Aranda CP. Schiffman G, Christianson LC. Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease. A pilot study. Chest 92, 204-212 (1987).
22. Ortqvist A, Hedlund J, Burman LA et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group. Lancet 351, 399-403 (1998).
23. Honkanen PO, Keistinen T, Miettinen L et al. Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older. Vaccine 17, 2493-2500 (1999).
24. Austrian R. Survillance of Pneumocccal Infection for Field Trials of Polyvalent Pneumococcal Vaccines. National Institute of Allergy and Infectious Diseases, MD, USA DVA-VDP 12-84 (1980).
25. Koivula I, Sten M, Leinonen M, Makela PH. Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial. Am. J. Med. 103, 281-290 (1997).
26. Sims RV, Steimann WC, McConville JK, King LR, Zwick WC, Schwartz JS. The clinical effectiveness of pneumococcal vaccine in the elderly. Ann. Intern. Med. 108, 653-657 (1988).
27. Butler JC, Breiman RF, Campbell JF et al. Pneumococcal polysaccharide vaccine efficacy. JAMA 270, 1826-1831 (1993).
28. Shapiro ED, Berg AT, Austrian R et al. The protective efficacy of polyvalent pneumococcal polysaccharide pneumonia. N. Engl. J. Med. 325, 1453-1460 (1991).
29. Dworkin MS, Ward JW, Hanson DL, Jones JL, Kaplan JE. Adult and adolescent Spectrum of HIV Disease Project. Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors and impact of vaccination. Clin. Infect. Dis. 32, 794-800 (2001).
30. Farr BM, Johnston BL, Cobb DK et al. Preventing pneumococcal bacteremia in patients at risk. Results of a matched case-control study. Arch. Intern. Med. 155, 2336-2340 (1995).
31. Gebo KA, Moore RD, Keruly JC, Chaisson RE. Risk factors for pneumococcal disease in human immunodeficiency virus-infected patients. J. Infect. Dis. 173, 857-862 (1996).
32. Guerrero M, Kruger S, Saitoh A et al. Pneumonia in HIV-infected patients: a case-control survey of factors involved in risk and prevention. AIDS 13, 1971-1975 (1999).
33. Breiman RF, Keller DW, Phelan MA et al. Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients. Arch. Intern. Med. 160, 2633-2638 (2000).
34. Navin TR, Rimland D, Lennox JL et al. Risk factors for community-acquired pneumonia among persons infected with human immunodeficiency virus. J. Infect. Dis, 181, 158-164 (2000).
35. Bentley DW, Ha K, Mamot K et al. Pneumococcal vaccine in the institutionalized elderly: design of a nonrandomized trial and preliminary results. Rev. Infect. Dis. 3(Suppl.), S71-S81 (1981).
36. Christenson B, Lundbergh P, Hedlund J, Ortqvist A. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: a prospective study. Lancet 357, 1008-1011 (2001).
37. Jackson LA, Neuzil KM, Yu O et al. Vaccine Safety Datalink. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N. Engl. J. Med. 348, 1747-1755 (2003).
38. Conaty S, Watson L, Dinnes J, Waugh N. The effectiveness of pneumococcal polysaccharide vaccines in adults: a systematic review of observational studies comparison with results from randomised controlled trials. Vaccine 22, 3214-3224 (2004).
39. Fine MJ, Smith MA, Carson CA et al. Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials. Arch. Intern. Med. 154, 2666-2677 (1994).
40. Cornu C, Yzebe D, Leophonte P, Gaillat J, Boissel JP, Cucherat M. Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials. Vaccine 19, 4780-4790 (2001).
41. Hutchinson BG, Oxman AD, Shannon HS, Lloyd S, Altmayer CA, Thomas K. Clinical effectiveness of pneumococcal vaccine. Meta-analysis. Can. Fam. Physician 45, 2381-2393 (1999).
42. Watson L, Wilson BJ, Waugh N. A systematic review of pneumococcal polysaccharide vaccine in adults. Vaccine 20, 2166-2173 (2002).
43. Moore RA, Wiffen PJ, Lipsky BA. Are the pneumococcal polysaccharide vaccines effective? Meta-analysis of the prospective trials. BMC Fam. Pract. 1, 1 (2000).
44. Puig Barberà J, Belenguer Barea A, Goterris Pinto M, Brines Benlliure MJ. Effectividad de la vacunación frente al neumococo en el anciano. Revisión sistemática y metaanálisis. Aten Primaria 30, 269-283 (2002).
45. Klatrersky J, Mommen F, Canteraire F, Safary A. Placebo-controlled pneumococcal immunization in patients with broncogenic carcinoma. Eur. J. Cancer Clin. Oncol. 22, 807-813 (1986).
46. Schwartz JS. Pneumococcal vaccine: clinical efficacy and effectiveness. Ann. Intern. Med. 96, 208-220 (1982).
47. Musher DM, Groover JE, Rowland JM et al. Antibody to capsular polysaccharides of Streptococcus pneumoniae: prevalence, persistence and response to revaccination. Clin. Infec. Dis. 17, 66-73 (1993).
48. Austrian R, Douglas RM, Schiffman G et al. Prevention of pneumococcal pneumonia by vaccination. Trans. Assoc. Am. Physicians 89, 184-194 (1976).
49. Willems, Sanders CR, Riddiough MA, Bell JR. Cost-effectiveness of vaccination against pneumococcal pneumonia. N. Engl. J. Med. 303, 553-559 (1980).
50. Office of Technology Assessment, US Congress. A Review of Selected Federal Vaccine and Immunization Policies: Based on Case Studies of Pneumococcical Vaccine. Government Printing Office, WA, USA (1979).
51. Ammet A, Baltussen R, Duru G et al. Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries. Clin. Infect. Dis. 31, 444-450 (2000).
52. Levy E. Evaluation socio-économique d'un vaccine contre l'infection pneumococcique. Rev. Epidemiol. Sante Publíque 29, 133-153 (1981).
53. Makela PH, Jokinen C, Pyhala R et al. Use of vaccines for respiratory infections: strategies for influenza and pneumococcal disease. J. Infect. Dis. 70, 141-148 (1990).
54. Sisk JE, Riegelman RK. Cost-effectiveness vaccination against pneumococcal pneumonia: an update. Ann. Intern. Med. 104, 79-86 (1986).
55. Sisk JE, Moskowitz AJ, Whang W et al. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA 278, 1333-1339 (1997).
56. Office of Technology Assessment, US Congress. Update of Federal Activities Regarding the Use of Pneumococcical Vaccine: a Technical Memorandum. Government Printing Office, WA, USA (1984).
57. Gable CB, Holzer SS, Engelhart L. Pneumococcal vaccine efficacy and associated cost savings. JAMA 264, 2910-2915 (1990).
58. Baltussen RMPM, Ament AJHA, Leidl RM, Van Furth R. Cost-effectiveness of vaccination against pneumococcal pneumonia in the Netherlands. Eur. J. Public Health 153-161 (1997).
59. De Graeve D, Lombaert G, Goossens H. Cost-effectiveness vaccination in adults and elderly persons in Belgium. Pharmacoeconomics 17, 591-601 (2000).
60. Postma MJ, Heijnen ML, Jager JC. Cost-effectiveness analysis of pneumococcal vaccination for elderly individuals in The Netherlands. Pharmacoeconomics 19, 215-222 (2001).
61. Jiménez FJ, Guallar P, Rubio C, Villasante P, Guallar E. Cost-effectiveness analysis of pneumococcal vaccination in the elderly Spanish population. Br. J. Med. Econ. 10, 193-202 (1996).
62. Whang W, Sisk JE, Heitjan DF, Moskowitz AJ. Probabilistic sensitivity analysis in cost-effectiveness. An application from a study of vaccination against pneumococcal bacteremia in the elderly. Int. J. Technol. Assess. Health Care 15, 563-572 (1999).
63. Postma MJ, Heijnen MA, Beutels P, Jager JC. Pharmacoeconomics of elderly vaccination against invasive pneumococcal infections: cost-effectiveness analyses and implications for The Netherlands. Expert Rev. Vaccines 2, 477-482 (2003).
64. Patrick KM, Woolley FRA. Cost-benefit analysis of immunity for pneumococcal pneumonia. JAMA 248, 473-477 (1981).
65. Laupacis A, Feeny D, Detsky A, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economical evaluations. CMAJ 146, 473-481 (1992).
66. Rose DN, Schechter CB, Sacks HS. Influenza and pneumococcal vaccination of HIV-infected patients: a policy analysis. Am. J. Med. 94, 160-168 (1993).
67. Nichol KL, Baken L, Wuorenma J et al. The health and economics benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. Arch. Intern. Med. 159, 2437-2442 (1999).
68. Vold Pepper P, Owens DK. Cost-effectiveness of pneumococcal vaccine in healthy younger adults. Med. Decis. Making 22(Suppl.), S45-S57 (2002).